Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis.
We investigated the effects of the iron chelator desferrioxamine on the expression of transferrin receptors (TfR) by CCRF-CEM human T-cell leukaemia and B16 mouse melanoma cells growing in tissue culture. Desferrioxamine (DFOA) enhanced TfR expression when added in the dose range of 10(-5)-10(-4) to CCRF-CEM cells, but was toxic to these cells, the lower concentrations producing a slowing of cell growth with a build up in S-phase, while higher concentrations caused cell death with a block at the G1/S-phase interface. These toxic effects are compatible with its previously reported inhibition of the non-haem iron containing (M2) subunit of ribonucleotide reductase. In marked contrast, DFOA caused the growth of B16 melanoma cells to arrest in G1, without loss of cloning efficiency, and resulted in a fall in TfR expression to approximately 50% of control values. These results suggested that the effects of DFOA on TfR expression were linked to DNA synthesis rather than to a more generalised inhibition of iron-dependent cellular processes. It was subsequently found that inhibition of the M2 subunit of ribonucleotide reductase in CCRF-CEM cells with 5 X 10(-5) M hydroxyurea, which is not an iron chelator, also enhanced TfR expression, as did thymidine and cytosine arabinoside, which have different enzyme targets. By measuring cellular DNA and RNA content simultaneously it was shown that all of these agents caused unbalanced growth, i.e., inhibited DNA synthesis more than RNA synthesis. In contrast, 6-thioguanine was more inhibitory to RNA synthesis, and treatment with this drug caused a fall in TfR expression. Thus, although CCRF-CEM cells treated with DFOA show enhanced TfR expression, similar effects are also seen with other inhibitors of DNA synthesis, provided that RNA synthesis is allowed to continue. These results provide further evidence that the regulation of TfR expression by proliferating cells is specifically linked to DNA synthesis rather than to the iron requirements of other cellular processes.
Hedley
D
D
Rugg
C
C
Musgrove
E
E
Taylor
I
I
D000818:Animals; D002460:Cell Line; D002470:Cell Survival; D004261:DNA Replication / Q000187:drug effects*; D003676:Deferoxamine / Q000494:pharmacology*; D005434:Flow Cytometry; D005453:Fluorescence; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D007399:Interphase; D007501:Iron / Q000378:metabolism; D007938:Leukemia / Q000235:genetics; D008545:Melanoma / Q000235:genetics; D051379:Mice; D012313:RNA / Q000096:biosynthesis*; D011956:Receptors, Cell Surface / Q000096:biosynthesis*; D011990:Receptors, Transferrin
D011956:Receptors, Cell Surface; D011990:Receptors, Transferrin; D012313:RNA; D007501:Iron; D003676:Deferoxamine; D006918:Hydroxyurea